Analyst Consensus ?
ConsensusBuy33 ratings
Bullish2678.8%
Neutral721.2%
Bearish00.0%
MetLife, Inc. · MET · FY2025 Q1 · Calendar Q2 2025
MetLife advances its strategy while managing spread and investment-income pressures
The current analysis supports a cautiously constructive view of MetLife's operating trajectory: earnings growth, retirement-solution demand, international sales and capital actions provide support, but spread pressure, variable investment income, real-estate exposure and macro sensitivity could limit durability.
Reported After market closeNYSEFinancial Services
$64.03B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $2.01
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $18.08B
Revenue surprise
—
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
+0.5%
Event window
SPY move
+0.7%
Same window
Abnormal move
-0.2%
Stock minus SPY
Volume
0.7×
Versus trailing sessions
Subsequent drift
+3.7%
Up to 20 sessions
METSPY benchmark
Ask FN2 about MET FY2025 Q1
Transcript, numbers and history already loaded
What drove MET's +0.5% move after FY2025 Q1 earnings?What changed in MET's guidance and outlook in FY2025 Q1?Give me the bull and bear case for MET after FY2025 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Relative to the prior-quarter analysis, MetLife reported continued earnings growth and emphasized a Talcott Resolution Life risk transfer, stronger Asia sales and further acquisition integration. The focus also shifted toward declining RIS spreads, below-implied-run-rate variable investment income and the need for a preliminary second-quarter update.
Guidance delta
Maintained; management also planned a preliminary variable investment income update for the second quarter.
Key takeaways
- Adjusted earnings grew year over year, supported by underwriting, volume growth and investment income, while foreign-currency and interest-margin pressures moderated results.
- Management highlighted retirement solutions, pension risk transfers, international sales and capital returns as central to the outlook.
- The Talcott Resolution Life risk transfer is intended to reduce legacy variable-annuity tail risk; execution and investment-income variability remain important watchpoints.
Management priorities
- Continue executing the New Frontier five-year strategy
- Expand retirement and income solutions and pension risk transfers
- Integrate the Mesirow and PineBridge acquisitions
- Develop international distribution, including the Japan banc-channel product
- Launch Chariot Re to enhance capital flexibility
Follow MET with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$100.76Current
$68Low
$95.14Average
$145High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 17, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| JP Morgan | Overweight | Overweight | Maintain | Oct 15, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Oct 12, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Oct 7, 2026 |
| Barclays | Overweight | Overweight | Maintain | Oct 7, 2026 |
| UBS | Buy | Buy | Maintain | Oct 6, 2026 |
| TD Cowen | Buy | Buy | Maintain | Oct 5, 2026 |
| Piper Sandler | Overweight | Neutral | Upgrade | Sep 22, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Aug 24, 2026 |
| Keefe, Bruyette & Woods | Outperform | Outperform | Maintain | Aug 11, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Jul 13, 2026 |
| Jefferies | Buy | Buy | Maintain | Jul 10, 2026 |
| B of A Securities | Buy | Buy | Maintain | Apr 14, 2026 |
| Citigroup | Buy | Buy | Maintain | Jul 23, 2024 |
| Argus Research | Buy | Buy | Maintain | May 22, 2024 |
| Goldman Sachs | Buy | Buy | Maintain | Jan 9, 2024 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 4, 2023 |
| Raymond James | Perform | Market Perform | Maintain | Sep 22, 2022 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 22, 2022 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Aug 19, 2022 |
| Deutsche Bank | Hold | Hold | Maintain | Apr 12, 2019 |
| Sandler O'Neill | Hold | Buy | Downgrade | Mar 19, 2019 |
| Bank of America | Buy | Neutral | Upgrade | Jan 16, 2019 |
| B. Riley Securities | Neutral | Neutral | Maintain | Jul 16, 2018 |
| B. Riley FBR | Neutral | Neutral | Maintain | Jul 16, 2018 |
| Atlantic Equities | Overweight | Neutral | Upgrade | Mar 26, 2018 |
| Argus | Buy | Buy | Maintain | Nov 6, 2017 |
| FBR Capital | Neutral | Buy | Downgrade | Oct 10, 2017 |
| Macquarie | Outperform | Outperform | Maintain | Feb 4, 2016 |
| Keefe Bruyette & Woods | Outperform | Outperform | Maintain | Oct 12, 2015 |
| Sterne Agee | Buy | Buy | Maintain | Oct 13, 2014 |
| Drexel Hamilton | Buy | Buy | Maintain | Jul 7, 2014 |
| Janney Montgomery Scott | Buy | Neutral | Upgrade | Jan 3, 2014 |
| Janney Capital | Buy | Neutral | Upgrade | Jan 3, 2014 |
Named analyst price targets
Upside is calculated against the persisted current price $100.76. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Mizuho Securities | Yaron Kinar | $109 | $97.16 | +8.2% | Oct 7, 2026 |
| Barclays | Analyst unavailable | $111 | $97.16 | +10.2% | Oct 7, 2026 |
| UBS | Michael Ward | $110 | $96.88 | +9.2% | Oct 6, 2026 |
| Piper Sandler | Paul Newsome | $110 | $96.64 | +9.2% | Sep 22, 2026 |
| Morgan Stanley | Bob Huang | $111 | $95.75 | +10.2% | Aug 24, 2026 |
| Wells Fargo | Analyst unavailable | $109 | $96.73 | +8.2% | Aug 19, 2026 |
| Barclays | Analyst unavailable | $97 | $96.26 | -3.7% | Aug 6, 2026 |
| Atlantic Equities | Analyst unavailable | $103 | $92.44 | +2.2% | Jul 15, 2026 |
| Jefferies | Suneet Kamath | $103 | $91.15 | +2.2% | Jul 10, 2026 |
| UBS | Michael Ward | $105 | $90.27 | +4.2% | Jul 8, 2026 |
| Barclays | Alex Scott | $94 | $90.46 | -6.7% | Jul 7, 2026 |
| Morgan Stanley | Analyst unavailable | $103 | $90.93 | +2.2% | Jul 6, 2026 |
| Piper Sandler | Analyst unavailable | $90 | $88.03 | -10.7% | Jun 24, 2026 |
| Piper Sandler | Analyst unavailable | $86 | $84.06 | -14.6% | May 26, 2026 |
| Morgan Stanley | Bob Huang | $93 | $83.5 | -7.7% | May 21, 2026 |
| Wells Fargo | Analyst unavailable | $95 | $77.98 | -5.7% | May 12, 2026 |
| Mizuho Securities | Yaron Kinar | $95 | $78.82 | -5.7% | May 8, 2026 |
| Barclays | Alex Scott | $93 | $80.16 | -7.7% | May 7, 2026 |
| Mizuho Securities | Yaron Kinar | $93 | $74.63 | -7.7% | Apr 13, 2026 |
| Evercore ISI | Analyst unavailable | $96 | $74.65 | -4.7% | Apr 9, 2026 |
| UBS | Analyst unavailable | $102 | $74.65 | +1.2% | Apr 9, 2026 |
| Mizuho Securities | Analyst unavailable | $100 | $78.89 | -0.8% | Feb 12, 2026 |
| Evercore ISI | Thomas Gallagher | $95 | $77.92 | -5.7% | Feb 10, 2026 |
| UBS | Analyst unavailable | $98 | $78.01 | -2.7% | Feb 5, 2026 |
| Mizuho Securities | Analyst unavailable | $102 | $77.08 | +1.2% | Jan 14, 2026 |
| Wells Fargo | Elyse Greenspan | $97 | $78.32 | -3.7% | Jan 13, 2026 |
| UBS | Analyst unavailable | $94 | $79.79 | -6.7% | Jan 8, 2026 |
| Barclays | Analyst unavailable | $90 | $79.47 | -10.7% | Jan 8, 2026 |
| Evercore ISI | Analyst unavailable | $97 | $81.77 | -3.7% | Jan 6, 2026 |
| Mizuho Securities | Analyst unavailable | $101 | $82.62 | +0.2% | Dec 15, 2025 |
| Morgan Stanley | Analyst unavailable | $101 | $83.22 | +0.2% | Dec 15, 2025 |
| Barclays | Analyst unavailable | $98 | $82.75 | -2.7% | Oct 8, 2025 |
| Morgan Stanley | Bob Huang | $97 | $82.7 | -3.7% | Oct 7, 2025 |
| Piper Sandler | John Barnidge | $84 | $79.07 | -16.6% | Sep 19, 2025 |
| Wolfe Research | Tracy Benguigui | $95 | $80.46 | -5.7% | Sep 15, 2025 |
| Morgan Stanley | Bob Huang | $98 | $77.74 | -2.7% | Jul 14, 2025 |
| Piper Sandler | John Barnidge | $94 | $82.49 | -6.7% | Apr 2, 2025 |
| Morgan Stanley | Analyst unavailable | $109 | $86.18 | +8.2% | Feb 28, 2025 |
| Piper Sandler | John Barnidge | $92 | $81.78 | -8.7% | Oct 2, 2024 |
| Barclays | Alex Scott | $91 | $77.52 | -9.7% | Sep 4, 2024 |
| Bank of America Securities | Joshua Shanker | $96 | $76.85 | -4.7% | Aug 1, 2024 |
| Morgan Stanley | Bob Huang | $83 | $69.92 | -17.6% | Jul 10, 2024 |
| Argus Research | Kevin Heal | $80 | $73.15 | -20.6% | May 22, 2024 |
| Piper Sandler | John Barnidge | $82 | $70.94 | -18.6% | May 6, 2024 |
| CFRA | Catherine Seifert | $77 | $72.67 | -23.6% | Mar 13, 2024 |
| Goldman Sachs | Alex Scott | $80 | $68.92 | -20.6% | Jan 8, 2024 |
| Mizuho Securities | Brett Linzey | $145 | $63.79 | +43.9% | Sep 14, 2023 |
| Morgan Stanley | Analyst unavailable | $90 | $72.68 | -10.7% | Feb 2, 2023 |
| Morgan Stanley | Analyst unavailable | $88 | $71.35 | -12.7% | Jan 10, 2023 |
| Goldman Sachs | Analyst unavailable | $78 | $73.58 | -22.6% | Jan 9, 2023 |
| J.P. Morgan | Analyst unavailable | $80 | $73.58 | -20.6% | Jan 6, 2023 |
| Jefferies | Analyst unavailable | $82 | $73.61 | -18.6% | Dec 9, 2022 |
| Morgan Stanley | Analyst unavailable | $87 | $74.01 | -13.7% | Nov 17, 2022 |
| Credit Suisse | Analyst unavailable | $77 | $67.39 | -23.6% | Aug 22, 2022 |
| Morgan Stanley | Analyst unavailable | $83 | $67.25 | -17.6% | Aug 17, 2022 |
| Morgan Stanley | Analyst unavailable | $79 | $64.14 | -21.6% | Aug 4, 2022 |
| Barclays | Analyst unavailable | $75 | $57.79 | -25.6% | Jul 14, 2022 |
| Evercore ISI | Analyst unavailable | $80 | $61.4 | -20.6% | Jul 6, 2022 |
| Morgan Stanley | Analyst unavailable | $78 | $61.58 | -22.6% | Jul 6, 2022 |
| Wolfe Research | Charles Lederer | $74 | $61.75 | -26.6% | Jun 22, 2022 |
| Morgan Stanley | Analyst unavailable | $80 | $67.23 | -20.6% | May 5, 2022 |
| Evercore ISI | Thomas Gallagher | $75 | $64.18 | -25.6% | Jan 5, 2022 |
| Goldman Sachs | Alex Scott | $77 | $58.92 | -23.6% | Dec 2, 2021 |
| Credit Suisse | Andrew Kligerman | $68 | $63.12 | -32.5% | May 13, 2021 |
| Argus Research | Kevin Heal | $72 | $65.2 | -28.5% | May 7, 2021 |
Track every rating change on MET the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationMetLife, Inc. operates as a leading global financial services entity, delivering an extensive array of services encompassing insurance, annuities, employee benefits, and asset management. The company manages its operations through five primary divisions: the U.S., Asia, Latin America, Europe, the Middle East and Africa (EMEA), and MetLife Holdings. Its broad insurance offerings include life, dental, group short-term and long-term disability, individual disability, pet, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans. MetLife also supports employers with administrative services-only (ASO) arrangements. Furthermore, it provides sophisticated financial instruments such as general and separate account contracts, synthetic guaranteed interest contracts, and private floating rate funding agreements.…
Historical context
All MET earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| MTB-PJ M&T Bank Corporation | FY2026 Q3 · Calendar Q4 2026 | — | — | M&T Bank highlights deposits, CRE growth and AI efficiency in Q3 |
| RF-PE Regions Financial Corporation | FY2026 Q3 · Calendar Q4 2026 | — | — | Regions Financial: Fee Growth and Technology Investment Lead Q3 Readout |
| MTB-PH M&T Bank Corporation | FY2026 Q3 · Calendar Q4 2026 | — | — | M&T: Loan and Deposit Growth Offset a Modest Q3 Earnings Decline |
| RF-PC Regions Financial Corporation | FY2026 Q3 · Calendar Q4 2026 | — | — | Regions Financial Maintains Growth Outlook as Fee Revenue Sets Records |
| TFC-PI Truist Financial Corporation | FY2026 Q3 · Calendar Q4 2026 | — | — | Truist refocuses on relationship banking while investing for growth |
| TRV The Travelers Companies, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +0.5% | Travelers posts strong Q3 underwriting results as AI investment continues |
Latest beats and misses
Who reports nextBeat on EPS
- IBKRFY2026 Q3 · October 15, 2026+0.3% EPS-3.9% move
- AAFY2026 Q3 · October 15, 2026+20.5% EPS+7.2% move
- JBHTFY2026 Q3 · October 15, 2026+0.6% EPS-2.0% move
- PLDFY2026 Q3 · October 15, 2026+105.9% EPS-2.7% move
- BNYFY2026 Q3 · October 15, 2026+4.4% EPS+3.2% move
- USB-PRFY2026 Q3 · October 15, 2026+1.5% EPS— move
Get the MET recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-04-16T00:02:45.914612+00:00
- Polygon adjusted daily market bars · 2026-10-17T03:00:40.643287+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-17T03:00:40.640545+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-17. For educational purposes only; not investment advice.